enVVeno Medical (NVNO) Liabilities and Shareholders Equity (2017 - 2026)

enVVeno Medical's Liabilities and Shareholders Equity history runs 10 years deep, the most recent figure standing at $26.1 million for Q1 2026.

• On a quarterly basis, Liabilities and Shareholders Equity fell 35.69% year-over-year to $26.1 million in Q1 2026; TTM through Mar 2026 was $124.6 million, a 29.58% decrease from a year earlier, with the FY2025 full-year figure at $29.6 million, down 34.24% from the prior year.
• Liabilities and Shareholders Equity retreated to $26.1 million in Q1 2026 per NVNO's latest filing, from $29.6 million in the prior quarter.
• Across five years, Liabilities and Shareholders Equity topped out at $54.2 million in Q1 2022 and bottomed at $26.1 million in Q1 2026.
• The 5-year median for Liabilities and Shareholders Equity is $41.0 million (2024), against an average of $40.2 million.
• Across the five-year window, Liabilities and Shareholders Equity sank 38.2% in 2023 and soared 79.36% in 2024, its largest moves.
• Year by year, Liabilities and Shareholders Equity stood at $41.7 million in 2022, then increased by 16.74% to $48.6 million in 2023, then decreased by 7.57% to $45.0 million in 2024, then sank by 34.24% to $29.6 million in 2025, then fell by 11.72% to $26.1 million in 2026.
• Per Business Quant, the three latest NVNO Liabilities and Shareholders Equity figures stand at $26.1 million (Q1 2026), $29.6 million (Q4 2025), and $32.4 million (Q3 2025).